Building on this approach, the FDA granted accelerated approval in April 2023 for Qalsody (tofersen), an ASO therapy designed to target SOD1 mRNA and reduce toxic protein synthesis in ALS patients with SOD1 mutations [113]. The gene discussed is SOD1; the disease is amyotrophic lateral sclerosis.